Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Standard Chemotherapy Plus Oral Everolimus as Adjuvant Therapy for LAR Breast Cancer Patients: A Randomized, Open-Label, Phase III Trial （POLARIS）

NCT07407517 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07407517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07407517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Standard Chemotherapy Plus Oral Everolimus as Adjuvant Therapy for LAR Breast Cancer Patients: A Randomized, Open-Label, Phase III Trial （POLARIS）
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
February 1, 2026
Completion date
February 1, 2033
Enrollment
904 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer females, triple negative breast cancer (tnbc)